Skip to main content
      RT @drdavidliew: Pregnancy is a minefield for RA pts:
      dx activity➡️preg risk
      PNL➡️preg risk, but dx activity pro

      David Liew drdavidliew

      4 years 5 months ago
      Pregnancy is a minefield for RA pts: dx activity➡️preg risk PNL➡️preg risk, but dx activity proxy? bring on Swedish/Danish linked data: 1739 RA preg matched 1:10 ⬆️pre-term/SGA risk with bDMARDs/PNL adj for dx activity: less bad, but still concern? OP0210 #EULAR2021 @RheumNow https://t.co/AlwFtmGcZH
      RT @Janetbirdope: Ever wonder why one drug works in a pt & not another? Study of bio markers in PsA from RCT of #upa

      Janet Pope Janetbirdope

      4 years 5 months ago
      Ever wonder why one drug works in a pt & not another? Study of bio markers in PsA from RCT of #upadacitinib vs #adalimumab shows diff pathways affected by each drug & some overlap too @RheumNow #EULAR2021 @eular_org OP0030 https://t.co/WifrVOIMkW
      RT @uptoTate: UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity and damage scores could be used in observational and controlled trials. #EULAR2021 @RheumNow https://t.co/Tw7OWyMcgX https://t.co/WiT0yGwVqK
      RT @AurelieRheumo: In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy associated w/ less DAS28 ESR Remi

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy associated w/ less DAS28 ESR Remission at 5 (45.0% in vs. 56.3% (p=0.03)) and 10 yrs (32.5% vs. 67.5% (p=0.06)) BUT no longer significant when adjusted for comorbidities! #EULAR2021 @Rheumnow #OP0098 https://t.co/pSrr1dzKFP
      RT @AurelieRheumo: Double hit”: #OP0015
      Phase IIA ABBV-3373 (Adalimumab linked to GC receptor modulator GRM) vs. PBO a

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Double hit”: #OP0015 Phase IIA ABBV-3373 (Adalimumab linked to GC receptor modulator GRM) vs. PBO and historic ADA show promising results with a satisfactory safety profile compared to ADA. A potential new IV drug in RA! #EULAR2021 @Rheumnow https://t.co/mqLtXx9zBI
      RT @AurelieRheumo: Acute Coronary Syndrom incidence in > 24,000 RA from Nordic registers followed up to 5 yrs = 5.5/1

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Acute Coronary Syndrom incidence in > 24,000 RA from Nordic registers followed up to 5 yrs = 5.5/1000 pyrs. After 5yrs RTX show > risk of ACS compared to ETA. In patient with >= 2 previous DMARDs ABA, INF and RTX > risk of ACS compared to ETA. #EULAR2021 @Rheumnow #OP0114 https://t.co/MjW9LI2cjt
      RT @AurelieRheumo: Patients with RA > 70yo and risk of severe infection: which therapeutic strategy is the safest?
      #E

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Patients with RA > 70yo and risk of severe infection: which therapeutic strategy is the safest? #EULAR2021 @Rheumnow #OP0116
      RT @AurelieRheumo: Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97 [1.13, 3.43] CDAI associated w/ > HR of major adverse CV events. HRs decrease during follow up. Tight and early disease control reduces CV burden! #EULAR2021 @Rheumnow #OP0101 https://t.co/A0ZYE4v8uf
      RT @AurelieRheumo: In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 mo

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 months. Stratified analysis: ⬆️disease activity for TNFi vs. non TNFi in patients of Black and Asian ethnicity. To be confirmed in independent cohorts. #EULAR2021 @Rheumnow #OP0117 https://t.co/7bFnOKR9uz
      RT @AurelieRheumo: MTX or ETA which one withdraw first? @RADoctor SEAM-RA trial: PROs following withdrawal of MTX or ETN

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      MTX or ETA which one withdraw first? @RADoctor SEAM-RA trial: PROs following withdrawal of MTX or ETN in RA patients with sustained SDAI remission receiving combination ETN+MTX. ETA > MTX for maintaining SDAI remission at W48 (49.5%-28.7% P=0.004) #EULAR2021 @Rheumnow #OP0118 https://t.co/MSOclXGMEK
      RT @AurelieRheumo: Rheum alliance trainee survey (n=302):
      87-96% report negative impact of COVID19 on Rheumatology trai

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Rheum alliance trainee survey (n=302): 87-96% report negative impact of COVID19 on Rheumatology training: -outpatient clinics (79%) -inpatient consultations (59%) -formal teaching (55%) -procedures (53%) and -ultrasonography (36%) #POS0051 @RheumNow #EULAR2021 @kristenyoung
      RT @AurelieRheumo: Can we predict pre-clinical RA-ILD?
      @Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, olde

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Can we predict pre-clinical RA-ILD? @Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, older age @ diag, mean DAS-28 over follow-up and MUC5B variant ▶️ preclinical ILD after 13 years of RA w/ AUC=0.82 CI 95% (0.72-0.91) (Sens 80%, Spe 56%) #POS0095 @Rheumnow #EULAR2021 https://t.co/bPyidNhNuO
      RT @AshimaMakol: Very informative #EULAR2021 WIN session on MIS-C @EULAR_org

      👉 Steroids early
      👉 IVIg in all
      👉

      Ashima Makol MD AshimaMakol

      4 years 5 months ago
      Very informative #EULAR2021 WIN session on MIS-C @EULAR_org 👉 Steroids early 👉 IVIg in all 👉 anticoagulant use remains variable #Coronary aneurysms ✅ occur during acute phase in MIS-C and improve with treatment ✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
      RT @Yuz6Yusof: Does skin #lupus respond differently to rituximab?Dr Carter @LucyCarter6 reported 75% cutaneous response

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      Does skin #lupus respond differently to rituximab?Dr Carter @LucyCarter6 reported 75% cutaneous response rate but overall non-response to tx was caused by skin domain. Interestingly, resistant skin post-tx was associated with low baseline #IFN scores #EULAR2021 #OP0134 @RheumNow https://t.co/JdtwdwNR4Z
      ×